XSHE
002030
Market cap1.25bUSD
Oct 09, Last price
6.03CNY
1D
1.17%
1Q
18.00%
Jan 2017
-49.67%
IPO
458.33%
Name
Daan Gene Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Daan Gene Co., Ltd. specializes in the research, development, manufacturing, and commercialization of clinical diagnostic reagents and instruments. The company's extensive product portfolio encompasses advanced solutions such as fluorescence quantitative PCR products, time-resolved series diagnostics, enzyme-linked immunoassay (EIA) kits, various diagnostic instruments, and specialized scientific research services. Beyond product offerings, the company extends its expertise to provide comprehensive medical examination and health management services. These encompass a wide range of offerings, from genetic susceptibility gene testing and tumor marker analysis to crucial cervical cancer screening and general routine physical examinations, alongside other personalized health support. Established in 2001, the company was originally known as Da An Gene Co., Ltd. of Sun Yat-Sen University. It is presently headquartered in Guangzhou, located in the People's Republic of China.
Key people
Dianhan Wei
Chairman of the Board · since 2025
Zhizheng Huang
Finance Director, Deputy General Manager, Director · since 2025
Yang Wang
Chief Marketing Officer, Deputy General Manager · since 2021
Taosheng Huang
Deputy General Manager, Chief Quality Officer · since 2025
Zhikun Liang
Deputy General Manager, Director · since 2025
Weijie Zhang
Chief Financial Officer, Deputy General Manager · since 2015
Jun'an Hong
Assistant to General Manager · since 2025
Lei Shi
Assistant to General Manager · since 2025
Yifan Yuan
Assistant General Manager · since 2025
Ping Zhang
Assistant to General Manager · since 2025
Jun Zeng
Deputy General Manager, Secretary of the Board · since 2025
Bin Zhang
Deputy General Manager, Secretary of the Board, Director · since 2019
Hongwei Chen
Vice Chairman of the Board, General Manager · since 2025
Wanyu Zhu
Director · since 2025
Jianbing Fan
Independent Director
Independent Director · since 2025
Xinchun Pei
Independent Director · since 2025
Headquarters & legal address
广州市高新技术产业开发区香山路19号
广州市, GD 510000
CN
广州市, GD 510000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||